SIMVASTATIN
PCOS, Insulin Resistance
Poznan University of Medical SciencesSmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the PCOS, Insulin Resistance cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Trans-Resveratrol Poznan University of Medical Sciences | Phase 4 | BB |
Same molecule, other indications
SIMVASTATIN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →